Compare
Rockwell Medical, Inc. vs Viridian Therapeutics, Inc. vs Kura Oncology, Inc. vs Spero Therapeutics, Inc.
| Latest fiscal year | Rockwell Medical, Inc. RMTI | Viridian Therapeutics, Inc. VRDN | Kura Oncology, Inc. KURA | Spero Therapeutics, Inc. SPRO |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $69.26M | $70.85M | $67.48M | $66.80M |
| Revenue growth (YoY) | -31.8% | n/m | +25.2% | +39.2% |
| Gross margin | 16.9% | n/a | n/a | n/a |
| Operating margin | -6.8% | -512.9% | -449.9% | 9.5% |
| Net margin | -7.7% | -483.6% | -412.9% | 12.8% |
| Net income | -$5.31M | -$342.60M | -$278.67M | $8.57M |
| EPS (Diluted) | -$0.15 | n/a | -$3.18 | $0.15 |
| Operating cash flow | -$659.0K | -$276.39M | -$64.06M | -$12.62M |
| Free cash flow | -$1.20M | -$276.89M | -$70.70M | n/a |
| Cash & equivalents | $10.71M | n/a | $149.10M | $40.27M |
| Total assets | $57.15M | $899.42M | $738.36M | $68.92M |
| Total liabilities | $20.16M | $177.25M | $564.23M | $9.90M |
| Shareholders' equity | $36.98M | $722.17M | $174.13M | $59.02M |
| Return on year-end equity | -14.4% | -47.4% | -160.0% | 14.5% |
| Shares outstanding | 39.41M | 101.83M | 87.86M | 56.41M |
Revenue, most recent five fiscal years
| Fiscal year | Rockwell Medical, Inc. | Viridian Therapeutics, Inc. | Kura Oncology, Inc. | Spero Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $69.26M Ended 2025-12-31 | $70.85M Ended 2025-12-31 | $67.48M Ended 2025-12-31 | $66.80M Ended 2025-12-31 |
| 1 year earlier | $101.49M Ended 2024-12-31 | $302.0K Ended 2024-12-31 | $53.88M Ended 2024-12-31 | $47.98M Ended 2024-12-31 |
| 2 years earlier | $83.61M Ended 2023-12-31 | $314.0K Ended 2023-12-31 | $0 Ended 2023-12-31 | $103.78M Ended 2023-12-31 |
| 3 years earlier | $72.81M Ended 2022-12-31 | $1.77M Ended 2022-12-31 | n/a | $53.51M Ended 2022-12-31 |
| 4 years earlier | $61.93M Ended 2021-12-31 | $2.96M Ended 2021-12-31 | n/a | $18.26M Ended 2021-12-31 |